FEB 07, 2017 10:00 AM PST

WEBINAR: Beyond 100,000: Insights & Lessons from Large-Scale Sequencing in the Cloud

Sponsored by: DNAnexus
  • Executive Director, Head of Genome Informatics, Regeneron Genetics Center
      Dr. Jeffrey G. Reid, Ph.D., is Executive Director, Head of Genome Informatics at the Regeneron Genetics Center, a large-scale sequencing initiative marrying exome sequence data with patient EMRs to improve patient outcomes and provide a blueprint for a future where genomics plays a central role in all aspects of drug development as well as the everyday practice of medicine. Dr. Reid focuses on the integration of EMR and sequence data in large data sets to provide insights into basic biology and improve patient outcomes. Before moving to Regeneron, Dr. Reid served for over six years as the leader of the next-generation sequencing informatics group at the Human Genome Sequencing Center at the Baylor College of Medicine. Dr. Reid has been involved in all aspects of high-throughput DNA sequence analysis applications, from the on-instrument primary analysis to algorithm development for data handling, variant calling, annotation, and all analysis steps in between. Using his experience in early big data analysis research from his work in relativistic heavy-ion collision physics computation in graduate school, Dr. Reid is a pioneer in the field of cloud-based genomics. Dr. Reid received his Ph.D. in physics from The University of Washington and his Bachelor's degree from Harvey Mudd College.


    DATE: February 7, 2017
    TIME: 10:00am PT, 1:00pm ET

    In this webinar, Jeffrey G. Reid, PhD, Executive Director and Head of Genome Informatics at Regeneron Pharmaceuticals, will share how the Regeneron Genetics Center (RGC) has built one of the world’s most comprehensive genetics databases, pairing the sequenced exomes and de-identified electronic health records of more than 100,000 people to date, with plans to ultimately sequence more than 250,000 people.  

    Described as the largest clinical sequencing undertaking in North America, the RGC collaborates with 30 institutions to marry healthcare provider and academic expertise with translational follow up, in essence making data actionable. By analyzing genomic and phenotypic data and making associations between genes and disease, the goal of the RGC collaboration is to make discoveries that inform and speed the drug development process. Ultimately, the hope is to improve patient healthcare outcomes through the development of new therapeutics for a broad range of serious medical conditions. 

    Regeneron selected DNAnexus to provide the cloud-based bioinformatics platform that enables various RCG research partnerships through the sharing and management of large-scale sequencing data and genomic tools. On February 7th, hear from one of the leading genetic experts discuss RGC’s integrated approach across genetic trait architectures and phenotypes, the underlying cloud infrastructure that makes possible the multi-institution collaboration, and key lessons learned from RGC’s pioneering genomic sequencing study. 

    Learning Objectives:

    • Why Regeneron is investing in human genetics
    • How the marriage between genotypes and phenotypes supports target drug discovery & validation

    Show Resources
    Show Resources
    • See more
    Connect with us